home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Thirteenth Arden House European Conference: Driving innovation, control and performance improvement on the critical path - the pivotal role of particle and powder technologies in dosage form manuf

 
  September 18, 2007  
     
 
Royal Pharmaceutical Society of Great Britain, AAPS and APS, Royal Pharmaceutical Society of Great Britain, 1 Lambeth High St, London
31/3/2008 - 2/4/2008


PROGRAMME
MONDAY 31 MARCH
SESSION 1: The drivers for change
Moderators: Richard Storey, AstraZeneca, UK and Rob Price, University of Bath, UK
What are the shortfalls of the current approaches to powder technology?
Fernando Muzzio, Rutgers University, USA
The current manufacturing environment
Neil Wilkinson, AstraZeneca, UK
Pharmaceutical powders: A journey from understanding to control to design
Chris Sinko, Pfi zer, USA
Continuous processes and life cycle management - the factory of the future
Jim Fox, GlaxoSmithKline, UK
Creating a regulatory environment to encourage innovation and change
Janet Woodcock, FDA, USA
Lunch
SESSION 2: Engineering and control of particle formation 1
Moderator: Alastair Florence, University of Strathclyde, UK
Nucleation simulation: what do we know about nucleation on the molecular scale?
Angelo Gavezzotti, University of Milan, Italy
Crystallisation engineering to aid drug product processing or performance
Amy Gillon, AstraZeneca, UK
Control of polymorphic systems during crystallization
Roger Davey, University of Manchester, UK
The use of ultrasonic crystallisation in providing a level of control in crystallisation procedures
Graham Ruecroft, Prosonix, UK
Round table discussion
Wine Reception
TUESDAY 1 APRIL
SESSION 2: (continued) Engineering and control of particle formation 2
Moderators: Rob Price, University of Bath, UK and Claire Madden, Molecular Profi les, UK
Particle formation and technologies, Particle size optimization
Ken Morris, Purdue, USA
Novel methodologies for the production of material for particulate systems
Jeremy Clarke, Pfi zer, UK
Surface interactions and their importance in performance of pharmaceutical formulations
Rob Price, University of Bath, UK
Investigations into the variation of physical properties of excipients
Sarah Dilworth, AstraZeneca, UK
Investigating powder processing
David Morton, Victorian College of Pharmacy, Monash University, Australia
Lunch
SESSION 3: Opportunities for optimizing particulate properties using crystal modifi cations
Moderator: Bill Jones, University of Cambridge, UK
The salt-cocrystal continuum
Scott Childs, Aptuit, USA
The use of solvates and hydrates as pharmaceutical forms
Gerard Coquerel, University of Rouen, France
The issue of cocrystal formation by grinding and the possible role of amorphous intermediates
Marc Descamps, University of Lille, France
Obtaining cocrystals and using synthons in the design of cocrystals
Roland Boese, University of Duisburg-Essen, Germany
Crystal structure prediction, an introduction and the potential for predicting cocrystals
Aurora Cruz Cabeza, University of Cambridge, UK
Round table discussion
Social programme with dinner
WEDNESDAY 2 APRIL
SESSION 4 Control of processes for particulate-based systems
Richard Storey, AstraZeneca, UK and David Morton, Victorian College of Pharmacy, Monash University,
Australia
Aspects of control in the formulation of particulate products
Jonathan Seville, University of Birmingham, UK
Characterization of materials for formulation control - oral & inhaled
Martyn Ticehurst, Pfi zer, UK
Use of Design of Experiments in identifying design space
TBA
Understanding particle surfaces/conditioning
Lars-Erik Briggner, AstraZeneca, Sweden
Understanding processes using PAT, case studies
Gavin Reynolds, AstraZeneca, UK
The criticality of sampling and relevance of measurement in process control
Dave Rudd, GlaxoSmithKline, UK
Lunch
SESSION 5: The intellectual property, regulatory and educational success
factors for facilitating this paradigm shift
Tom Sam, Organon, Netherlands and Ken Leiper, Benson Associates, UK
The intellectual property challenges arising from enhanced knowledge of powders, processability
and isolation
TBA
A regulatory perspective of the related challenges for industry, agencies, pharmacopoeias
and the qualifi ed person
Gordon Munro, Watson Pharmaceuticals, USA
The adoption of new technologies requires new skills – how will the global
challenge be facilitated?
Fernando Muzzio, Rutgers University, USA
Close of conference
 
 
Organized by: Royal Pharmaceutical Society of Great Britain
Invited Speakers: LEARN FROM A TEAM OF EXPERTS
Programme Committee
Conference chairs: Richard Storey (Associate Principle Scientist, AstraZeneca, UK) and Rob Price
(Reader in Pharmaceutical Technology, University of Bath, UK)
Alastair Florence (University of Strathclyde, UK), Ken Leiper (Benson Associates, UK), Claire Madden-
Smith (Molecular Profi les, UK), David Morton (Victorian College of Pharmacy, Monash University,
Australia), Bill Jones (University of Cambridge, UK), Tom Sam (Organon, Netherlands)
 
Deadline for Abstracts: ASAP
 
Registration: DELEGATE FEES
Delegate fees are £950 for members of RPSGB, APS or AAPS or £995 for non-members. Fees are
inclusive of lunches and refreshments, a full social programme (including dinner on the last evening) and
comprehensive course documentation.
REGISTER BEFORE 30 NOVEMBER 2007 FOR THE EARLY BIRD FEE OF £895
E-mail: science@rpsgb.org
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.